Skip to main content
SpringerLink
Log in

CE not improved by outcomes-based pricing

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk

  2. 2017 US dollars

References

  1. Kazi DS, et al. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. Annals of Internal Medicine : 3 Apr 2018. Available from: URL: http://dx.doi.org/10.7326/M17-3367.

  2. Mailankody S, et al. Money-Back Guarantees for Expensive Drugs: Wolf's Clothing but a Sheep Underneath. Annals of Internal Medicine : 3 Apr 2018. Available from: URL: http://dx.doi.org/10.7326/M18-0539.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CE not improved by outcomes-based pricing. PharmacoEcon Outcomes News 801, 6 (2018). https://doi.org/10.1007/s40274-018-4861-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4861-y

Search

Navigation